Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015844 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL56398 | 1.00 | — | — | |
| SCHEMBL730035 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL12500356 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL1470503 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL1470569 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL67396 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL2873944 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL514779 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL2877322 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744089-A1 | SELECTIVE DEPOSITION OF ALUMINUM-CONTAINING DIELECTRIC MATERIAL ON DIELECTRIC OVER METAL UTILIZING ALKYNES | Versum Materials US, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP LABS 114, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025226985-A1 | PASSIVATION OF POLYSILICON MATERIAL AND SELECTIVE DEPOSITION OF DIELECTRIC MATERIAL UTILIZING ALKYNES | VERSUM MATERIALS US, LLC (US) | 2025-10-30 | — | — | WO | claimed |
| WO-2025038887-A1 | SELECTIVE DEPOSITION OF ALUMINUM-CONTAINING DIELECTRIC MATERIAL ON DIELECTRIC OVER METAL UTILIZING ALKYNES | VERSUM MATERIALS US, LLC (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2024211865-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | OMEGA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| US-20240327730-A1 | Deydrogenative Coupling of Low-Value Light Alkanes to Sustainable Aviation Fuel | Alliance for Energy Innovation, LLC | 2024-10-03 | — | — | US | claimed |
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2023225621-A2 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-3484898-B1 | METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE | MOMENTIVE PERFORMANCE MAT INC (US) | 2023-06-28 | — | — | EP | claimed |
| US-7208647-B2 | Process for the conversion of natural gas to reactive gaseous products comprising ethylene | SYNFUELS INTERNATIONAL, INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20050065392-A1 | Process for the conversion of natural gas to reactive gaseous products comprising ethylene | SYNFUELS INTERNATIONAL, INC. (US) | 2005-03-24 | — | — | US | claimed |
| US-20050065391-A1 | Process for the conversion of natural gas to hydrocarbon liquids | SYNFUELS INTERNATIONAL, INC. (US) | 2005-03-24 | — | — | US | claimed |
| EP-0396875-B1 | Method of stabilizing the frequency of semiconductor laser and apparatus therefor | NIPPON TELEGRAPH & TELEPHONE (JP) | 1995-09-06 | — | — | EP | claimed |
| CN-1025564-C | Process for the preparation of phenyl epoxy hydroxy acid esters | SMITHKLINE BECKMAN CORP (US) | 1994-08-03 | — | — | CN | claimed |
| CN-1074212-A | The crystallization of the optically active isomer of leukotriene antagonist | SMITHKLINE BEECHAM CORP (US) | 1993-07-14 | — | — | CN | claimed |
| EP-0396875-A2 | Method of stabilizing the frequency of semiconductor laser and apparatus therefor | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 1990-11-14 | — | — | EP | claimed |
| CN-1008091-B | Process for preparing leukotriene antagonists | SMITHKLINE BECKMAN CORP (US) | 1990-05-23 | — | — | CN | claimed |
| CN-1041359-A | PROCESS FOR PREPARING LEUKOTRIENE ANTAGONIST PRODRUGS | SMITHKLINE BECKMAN CORP (US) | 1990-04-18 | — | — | CN | claimed |
| CN-1040586-A | Process for preparing leukotriene antagonists | SMITHKLINE BECKMAN CORP (US) | 1990-03-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | NSUN3, NSUN2, LDLR | TSHR 545/4885THRB 753/4885SMN1; SMN2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.